To cap off the first year of the LungCancerRx podcast, cohosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, share how they first came together and what they see as their mission for the series moving forward. “I think we want to stop the gatekeeping of information,” Dr. Singhi explained.

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation.

“I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cancer Institute in Boston. Dr. Rotow explains how key data from the HARMONi, COMPEL, and MARIPOSA-2 studies and a wave of new treatment options on the horizon have led to “good challenges” in non-small cell lung cancer care.

In this episode of LungCancerRx, the experts talk about key trials presented at the World Conference on Lung Cancer, and the rapidly shifting landscape in lung cancer treatment, which now can be treated as multiple different diseases. Cohost Eric Singhi, MD, is joined by Bruna Pellini, MD, Antonio Calles, MD, and Stephen Liu, MD.

In this episode of LungCancerRx, the experts talk about the FLAURA2 and HARMONi data presented at the World Conference on Lung Cancer and what the findings mean for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Recorded onsite in Barcelona, Spain, cohost Eric Singhi, MD, from Houston, Texas, is joined by Bruna Pellini, MD, from Moffitt Cancer Center and Research Institute in Tampa, Florida; Antonio Calles, MD, from Hospital General Universitario Gregorio Marañón in Madrid, Spain; and Stephen Liu, MD, from Lombardi Comprehensive Cancer Center of Georgetown University in Washington, DC.

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, to talk about the complexities of treating advanced EGFR-positive NSCLC. Dr. Lovely shares how she talks with patients about the latest data and recent trials.

When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” says patient advocate Jill Feldman. In the second episode of the LungCancerRx video podcast, cohosts Fawzi F. Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit; Eric K. Singhi, MD, a thoracic oncologist in Houston; and Aakash Desai, MD, MPH, an assistant professor at the University of Alabama at Birmingham’s O’Neal Cancer Center, ask Feldman about how physicians can better empower patients when making difficult therapy choices. “I started using ‘informed decision-making’ because you cannot have ‘shared decision-making’ if patients aren’t completely informed,” she explains.

In the first episode of the LungCancerRx video podcast, cohosts Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama at Birmingham’s O'Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit; are joined by patient advocate Jill Feldman. They talk about her experience with lung cancer – both her own and her family members’ – and why it is so important for individual patients to be heard and placed at the center of care. Communication is key to maintaining that focus, and the hosts seek insights into how providers can be present during appointments and how patients cope.